DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Brunton LL. A positive feedback loop contributes to the deleterious
effects of angiotensin. Proc Natl Acad Sci USA, 2005,
102:14483–14484.
Cazzola M, Matera MG. Novel long acting bronchodilators for
COPD and asthma. Br J Pharmacol, 2008, 155:291–299.
Cheng J, Kamiya K, Kodama I. Carvedilol: Molecular and cellular
basis for its multifaceted therapeutic potential.
Cardiovasc Drug Rev, 2001, 19:152–171.
Chidiac P, Hebert TE, Valiquette M, et al. Inverse agonist activity
of β-adrenergic antagonists. Mol Pharmacol, 1994, 45:
490–499.
Cleland JG. β-Blockers for heart failure: Why, which, when, and
where. Med Clin North Am, 2003, 87:339–371.
Coats AJS. β-adrenoceptor antagonists in elderly patients with
chronic heart failure. Therapeutic potential of third generation
agents. Drugs Aging, 2006, 23:93–99.
Cruickshank JM. β-Blockers and diabetes. The bad guys come
good. Cardiovasc Drugs Ther, 2002, 16:457–470.
Czuriga I, Riecansky I, Bodnar J, et al. for the NEBIS
Investigators Group. Comparison of the new cardioselective
β-blocker nebivolol with bisoprolol in hypertension: The
nebivolol, bisoprolol multicenter study (NEBIS). Cardiovasc
Drugs Ther, 2003, 17:257–263.
Dandona P, Ghanim H, Brook DP. Antioxidant activity of
carvedilol in cardiovascular disease. J Hypertension, 2007,
25:731–741.
deBoer RA, Voors AA, vonVeldhuisen DJ. Nebivolol: Third generation
beta blockade. Expert Opin Pharmacother, 2007,
8:1539–1550.
de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant
activity of nebivolol in the rat aorta. J Cardiovasc
Pharmacol, 2004, 43:148–153.
DiBari M, Marchionni N, Pahor M. β-blockers after acute
myocardial infarction in elderly patients with diabetes mellitus:
Time to reassess. Drugs Aging, 2003, 20:13–22.
Ding B, Abe J, Wei H, et al. A positive feedback loop of PDE3
and ICER leads to cardiomyocyte apoptosis. Proc Natl Acad
Sci USA, 2005, 102:14771-14776.
Dobre D, Haarjer-Ruskamp FM, Voors AA, van Veldhuisen DJ.
β adrenoceptor antagonists in elderly patients with heart failure.
A critical review of their efficacy and tolerability. Drugs
Aging, 2007, 24:1031–1094.
Donnelly R, Macphee GJ. Clinical pharmacokinetics and kineticdynamic
relationships of dilevalol and labetalol. Clin
Pharmacokinet, 1991, 21:95–109.
Drazen JM, O’Byrne PM. Risks of long acting beta-agonists in
achieving asthma control. N Engl J Med, 2009, 360:
1671–1672.
Dunne F, Kendall MJ, Martin U. β-Blockers in the management
of hypertension in patients with type 2 diabetes mellitus: Is
there a role? Drugs, 2001, 61:428–435.
Dzierba AL, Sanja J. Chronic obstructive pulmonary disease in
the elderly: An update on pharmacological management.
Drugs Aging, 2009, 26:447–456.
Ellison KE, Gandhi G. Optimizing the use of β-adrenoceptor
antagonists in coronary artery disease. Drugs, 2005, 65:
787–797.
Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive
hypertrophy and heart failure in β 1
-adrenergic receptor transgenic
mice. Proc Natl Acad Sci USA, 1999, 96:7059–7064.
Fanta CH. Asthma. N Engl J Med, 2009, 360:1002–1014.
Faulds D, Hollingshead LM, Goa KL. Formoterol. A review of
its pharmacological properties and therapeutic potential in
reversible obstructive airways disease. Drugs, 1991, 42:
115–137.
Felix SB, Stangl V, Kieback A, et al. Acute hemodynamic effects
of β-blockers in patients with severe congestive heart failure:
Comparison of celiprolol and esmolol. J Cardiovasc
Pharmacol, 2001, 38:666–671.
Fernandez-Lopez JA, Remesar X, Foz M, Alemany M.
Pharmacological approaches for the treatment of obesity.
Drugs, 2002, 62:915–944.
Fitton A, Benfield P. Dopexamine hydrochloride. A review of its
pharmacodynamic and pharmacokinetic properties and therapeutic
potential in acute cardiac insufficiency. Drugs, 1990,
39:308–330.
Fitton A, Sorkin EM. Sotalol. An updated review of its pharmacological
properties and therapeutic use in cardiac arrhythmias.
Drugs, 1993, 46:678–719.
Fleckenstein A. New insights into the mechanism of actions of
amphetamines. Annu Rev Pharmacol, 2007, 47:691–698.
Forray C, Bard JA, Wetzel JM, et al. The α 1
-adrenergic receptor
that mediates smooth muscle contraction in human prostate
has the pharmacological properties of the cloned human α 1c
subtype. Mol Pharmacol, 1994, 45:703–708.
Freemantle N, Cleland J, Young P, et al. β Blockade after
myocardial infarction: systematic review and meta regression
analysis. BMJ, 1999, 318:1730–1737.
Fung JW, Yu CM, Kum LC, et al. Role of β-blocker therapy in
heart failure and atrial fibrillation. Cardiac Electrophysiol Rev,
2003, 7:236–242.
Gauthier C, Langin D, Balligand JL. β 3
adrenoceptors in the cardiovascular
system. Trends Pharmacol Sci, 2000, 21:426–431.
Galderisi M, D’Errico A. β-blockers and coronary flow reserve: The
importance of a vasodilatory action. Drugs, 2008, 68:579–590.
Gazzola M, Materea MC, Donner CF. Inhaled β 2
-adrenoceptor
agonists. Cardiovascular safety in patients with obstructive
lung disease. Drugs, 2005, 65:1595–1610.
Gerstman BB, Jolson HM, Bauer M, et al. The incidence of
depression in new users of β-blockers and selected antihypertensives.
J Clin Epidemiol, 1996, 49:809–815.
Gielen W, Cleopohas TJ, Agrawal R. Nevivolol: A review of its
clinical and pharmacological characteristics. Int J Clin
Pharmacol Ther, 2006, 44:344–357.
Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of
asthma management: Toward understanding how long acting
β 2
adrenoceptor agonist enhance the clinical efficacy of inhaled
corticosteroids. Br J Pharmacol, 2008, 153:1080–1104.
Goldsmith DR, Keating GM. Budesonide/fomoterol: A review
of its use in asthma. Drugs, 2004, 64:1597–1618.
Goldsmith DR, Plosker GL. Doxazosin gastrointestinal therapeutic
system. A review of its use in benign prostatic hyperplasia.
Drugs, 2005, 65:2037–2047.
Goldstein S. Benefits of β-blocker therapy for heart failure. Arch
Intern Med, 2002, 162:641–648.
Gottlieb SS, McCarter RJ, Vogel RA. Effect of β-blockade on
mortality among high-risk and low-risk patients after myocardial
infarction. N Engl J Med, 1998, 339:489–497.
Grimm RH Jr. Antihypertensive therapy: taking lipids into consideration.
Am Heart J, 1991, 122:910–918.
Guimarães S, Moura D. Vascular adrenoceptors: An update.
Pharmacol Rev, 2001, 53:319–356.
331
CHAPTER 12
ADRENERGIC AGONISTS AND ANTAGONISTS